SCHEMBL21312600

SCHEMBL21312600

Cc1ccccc1-c1ccc(Oc2[nH]nnc2C(=O)O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 1/20 0.43
▸ PPARA Q07869 1/20 0.43
▸ MCL1 Q07820 1/20 0.40
▸ BTK Q06187 1/20 0.40
▸ HAO1 Q9UJM8 3/20 0.38
▸ LTB4R Q15722 1/20 0.37
▸ MGLL Q99685 1/20 0.37
▸ NR1H4 Q96RI1 1/20 0.36
▸ ESR1 P03372 1/20 0.36
▸ HSP90AA1 P07900 1/20 0.35
▸ HSP90AB1 P08238 1/20 0.35
▸ PRKAB2 O43741 1/20 0.35
▸ PRKAG1 P54619 1/20 0.35
▸ PRKAA2 P54646 1/20 0.35
▸ PRKAA1 Q13131 1/20 0.35
▸ PRKAG3 Q9UGI9 1/20 0.35
▸ PRKAG2 Q9UGJ0 1/20 0.35
▸ PRKAB1 Q9Y478 1/20 0.35
▸ CA12 O43570 1/20 0.35
▸ CA1 P00915 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21312326 0.85 ALPL (0.45) PPARGPPARAHAO1PRKAB2PRKAG1
SCHEMBL21296854 0.85 HAO1 (0.44) MCL1HAO1PRKAG1PRKAA1PRKAB1
SCHEMBL21296864 0.85 PPARG (0.43) PPARGPPARAHAO1PRKAB2PRKAG1
SCHEMBL21312599 0.85 ALPL (0.42) HAO1PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL25463985 0.84 MKNK1 (0.46) HAO1ESR1
SCHEMBL25464969 0.83 HAO1 (0.34) HAO1MGLLPRKAB2PRKAG1PRKAA2
SCHEMBL23320028 0.83 PPARG (0.48) PPARGPPARAMCL1
SCHEMBL29968357 0.83 PPARG (0.48) PPARGPPARAMCL1
SCHEMBL21296970 0.83 ALPL (0.42) HAO1MGLLPRKAG1PRKAA1PRKAB1
SCHEMBL25464951 0.82 PRKAB2 (0.41) PPARGPPARAMCL1HAO1PRKAB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11389456-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-07-19 — — US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 — — US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 — — US disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, LOX PPARG 959/4885PPARA 1870/4885MCL1 3573/4885
US-11389456-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, LOX PPARG 959/4885PPARA 1870/4885MCL1 3573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback